Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.52 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.52 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.52 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RARB | P10826 | 6/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terephthalic Acid SCHEMBL8743595 | 0.98 | ALDH1A1 (0.56) | KMT2ABLMTDP1ALDH1A1TP53 | |
| SCHEMBL589884 | 0.98 | ALDH1A1 (0.56) | KMT2ABLMTDP1ALDH1A1TP53 | |
| Bromide SCHEMBL28688593 | 0.96 | ALDH1A1 (0.54) | KMT2ABLMTDP1ALDH1A1TP53 | |
| SCHEMBL11464670 | 0.96 | ALDH1A1 (0.54) | KMT2ABLMTDP1ALDH1A1TP53 | |
| Aminomethylbenzoic Acid SCHEMBL8000841 | 0.92 | ALDH1A1 (0.50) | KMT2ABLMTDP1ALDH1A1TP53 | |
| SCHEMBL9467136 | 0.92 | SRD5A2 (0.55) | KMT2ABLMTDP1ALDH1A1TP53 | |
| Sulfuric Acid SCHEMBL7321645 | 0.90 | CA12 (0.50) | KMT2ABLMTDP1ALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL11111164 | 0.88 | RARB (0.58) | KMT2AALDH1A1TP53TSHRRARB | |
| SCHEMBL4252326 | 0.87 | SRD5A2 (0.62) | KMT2AALDH1A1TAAR1SMN1; SMN2LOXL2 | |
| Hydrochloric Acid SCHEMBL7132238 | 0.86 | TSHR (0.63) | KMT2AALDH1A1TP53TSHRRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122054801-A | Solar cell, preparation method thereof, photovoltaic module, power utilization device and power generation device | 宁德时代新能源科技股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4633678-A1 | HYDROGEL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Wake Forest University Health Sciences (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2025-06-19 | — | — | US | disclosed |
| WO-2025121401-A1 | PYRAZOLE COMPOUND AND HARMFUL ORGANISM CONTROL AGENT | 日産化学株式会社 | 2025-06-12 | — | — | WO | disclosed |
| US-20240366552-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2024-11-07 | — | — | US | disclosed |
| WO-2024130101-A1 | HYDROGEL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240115543-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2024-04-11 | — | — | US | disclosed |
| WO-2024028604-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2023-08-17 | — | — | US | disclosed |
| EP-4135738-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | Cohbar Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-0915700-B1 | USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS | MYRIAD GENETICS INC (US) | 2006-03-22 | — | — | EP | disclosed |
| CN-1541211-A | Derivatives of N-(arylsulfonyl) beta-aminoacids comprising substituted aminomethyl group, prepn. method thereof and pharmaceutical compsns. contg same | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-10-27 | — | — | CN | disclosed |
| EP-0386839-B1 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME (GB) | 1997-01-15 | — | — | EP | disclosed |
| US-5266718-A | Antidiabetic agents | ADIR ET COMPAGNIE (FR) | 1993-11-30 | — | — | US | disclosed |
| US-5231102-A | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME, LTD. (GB) | 1993-07-27 | — | — | US | disclosed |
| EP-0386839-A2 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1990-09-12 | — | — | EP | disclosed |
| US-4443477-A | ANTICOAGULANTS, ANTILIPEMIC AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1984-04-17 | — | — | US | disclosed |
| US-4221815-A | HYPOGLYCEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-09-09 | — | — | US | disclosed |
| US-4158063-A | Acylamino(alkyl)benzene derivatives and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-06-12 | — | — | US | disclosed |
| US-4136197-A | HYPOGLYCAEMICALLY AND HYPOLIPIDAEMICALLY EFFECTIVE N-SUBSTITUTED CARBOXYLIC ACID AMIDES | BOEHRINGER MANNHEIM GMBH (DE) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115543-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | HTR1A 1133/4885ADRA2A 86/4885SLC6A2 495/4885 |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | HTR1A 1133/4885ADRA2A 86/4885SLC6A2 495/4885 |
| US-20240366552-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | HTR1A 1133/4885ADRA2A 86/4885SLC6A2 495/4885 |
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | HTR1A 1133/4885ADRA2A 86/4885SLC6A2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.